In the complex, competitive and unpredictable pharmaceutical, Eli Lilly and Co (LLY) is a notable player that is gaining even more notoriety. The company is currently making significant strides in diabetes care and weight loss medications; however, these advancements have not come without their challenges. It has recently experienced periods of management transitions and has been managing substantial debt. Such debts were incurred to invest in research and development, notably for Weight loss drugs like Mounjaro (tirzepatide), Zepbound and Retatrutide, which are at the forefront of Eli Lilly's recent success.
LLY has strategically launched a direct-to-consumer platform, "LillyDirect". This move reflects the company's adaptation to digital platforms and increased demand of their product, addressing a significant barrier nowadays in the acquisition of such drugs, particularly in the weight loss segment: buying them from a supplier that hasn't run out of stocks yet.